Aloe vera (Aloe barbadensis) sits in an unusual position in cosmetic biology. Its use in skincare predates modern dermatology by several thousand years, and the bioactivity of its inner-leaf gel is among the best-documented in botanical medicine. What sat undescribed inside that gel until recently is a population of nanoscale extracellular vesicles released by the parenchymal cells of the aloe leaf. Those vesicles are now characterizable, isolable, and suitable as a scalable dermocosmetic active.
Treating aloe-derived EVs as if they were just another plant-EV source misses what makes them practical. Aloe is one of a small number of plant species where the historical cosmetic record, the modern phytochemistry, and the EV biology line up.
What is in an aloe-derived EV preparation
Aloe leaf parenchyma is a hydrated polysaccharide-rich tissue. Cells in this tissue release extracellular vesicles in the size range typical of plant-derived EVs, with particle diameters concentrated in the small-EV range and a population profile measurable by NTA. The cargo profile of these vesicles, characterized through proteomic and biochemical analyses across multiple research groups, includes three categories of bioactive content that are relevant to skin formulation.
The first is the antioxidant fraction. Aloe leaves contain phenolic compounds and free-radical-scavenging molecules that are partially encapsulated in the EV population. These compounds are well-characterized antioxidants in cell-based assays and contribute to the biological activity of aloe preparations more broadly.
The second is the skin-soothing fraction. Signalling lipids and small bioactive molecules associated in cell-based research with calming and conditioning effects on cultured skin cells are present in the EV population. The cosmetic literature on aloe extract skin-soothing activity has documented these classes of molecules for decades; the EV-encapsulated subset of them is the more recent finding.
The third is the skin-renewal fraction. Growth factor-associated proteins and miRNA species studied for their role in supporting skin cell renewal and proliferation in cell-based research are present in the EV cargo. This category aligns with the cross-kingdom EV literature, which has documented preclinical effects of plant-EV cargo on mammalian skin cells across multiple plant sources.
Why aloe is operationally practical
Three practical properties make aloe a defensible source for scalable dermocosmetic EV manufacturing.
Biomass scalability. Aloe is one of the most agriculturally tractable plants in cosmetic supply chains. It grows under a wide range of conditions, accepts greenhouse and outdoor cultivation, has predictable harvest cycles, and produces high biomass per unit area. The economics of EV isolation depend on the cost-per-gram of the input biomass; aloe is closer to commodity-economy than to specialty botanical inputs.
Regulatory familiarity. Aloe vera as a cosmetic ingredient has decades of regulatory history under Health Canada, the EU Cosmetic Regulation, and FDA cosmetic frameworks. The base ingredient is well-characterized for safety. EV preparations from aloe operate as a more specific, more characterized form of the same source material, with the additional characterization data manufacturers like BioThera apply on top.
Consumer recognition. Aloe has 3,000 years of cosmetic and folk-medicine history and is one of the most consumer-recognized active ingredients in skincare globally. For a category, EVs, that is itself unfamiliar to most consumers, sourcing from a familiar species lowers the cognitive load on the product story without requiring marketing to overstate the EV science.
The honest version of what aloe-derived EVs do
It is worth stating clearly what an aloe-derived EV preparation is and is not, in the same vocabulary the broader EV field uses.
It is a characterized population of plant-derived nanoscale particles, with a cargo profile dominated by antioxidant, soothing, and skin-renewal-associated molecule classes, suitable for topical cosmetic application as a characterized active. The mechanistic basis for its activity is supported by the cross-kingdom EV literature, by the broader phytochemistry of aloe, and, for a specific product, by that product's own characterization data.
It is not a therapeutic agent. It is not a substitute for medical-grade interventions. It is not a cure or treatment for any condition, and credible manufacturers do not present it that way. The framing under Health Canada Cosmetic Regulations is that it is a cosmetic active with documented antioxidant and soothing activity in the EV preparation form, characterized to standards substantially exceeding what the cosmetic category requires.
Where this fits in the BioThera platform
BioThera's first commercial application, the mPDEV Serum, is built around plant-derived extracellular vesicles. Aloe is one of the medicinal plant sources that fits the operational profile we built the platform to deliver: scalable biomass, characterized cargo, regulatory familiarity, and a consumer-side story that does not have to outpace the science. The platform is designed to be source-flexible at scale; the choice to begin with medicinal plant biomass is a calibration to current evidence and current regulatory pathways, not a permanent constraint.
For clinicians: the question to ask of any aloe-derived EV product is the same set of five questions we apply to any EV product. Source specificity, particle concentration, batch CoA, isolation method, cold chain. The history of aloe in cosmetics does not exempt an EV product from those criteria. It is a feature of the source. The characterization is what makes the product.